Tiziana Life Sciences (TLSA) Stock Analysis & Winston Score

Tiziana Life Sciences is a small British biotechnology company that develops experimental medicines for serious diseases. Its main focus is on drugs that target the immune system, particularly for conditions like multiple sclerosis, liver disease, and certain cancers. The company does not yet sell any approved products to patients or doctors.

Tiziana earns no product revenue today because all of its drug candidates are still in clinical trials. It is headquartered in the United Kingdom with operations also in the United States, and it relies on raising money from investors to fund its research. With a market cap of around $100 million and no approved medicines, the company's future depends almost entirely on whether its lead drug candidates succeed in clinical trials — failure in any key trial would be a significant setback for the business.

Winston Score History

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

Revenue data limited

EPS Growth

-69.2% YoY

YoY Growth Rate

Earnings declining

Insider Activity

49.8%ownership

↑ Rising

Insiders increasing their stake — aligned with shareholders

Cash Runway

~2 months

$4M cash & investments

Quarterly Free Cash Flow

↓ Burn rate worsening

Short runway — potential dilution ahead through share issuance

Cash watch

Tiziana Life Sciences has less than a year of cash at its current burn rate. Growth investors should watch for potential share dilution from future fundraising — that directly reduces your ownership.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Gross Margin

N/A

—

Data not available

Operating Margin

N/A

—

Data not available

ROCE

-4499.3%

Weak — -4499.3% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales YoY

N/A

—

Data not available

EPS YoY

N/A

—

Data not available

EPS Consistency

0/8 quarters

Earnings rarely grow — volatile business

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Cash Conversion

N/A

—

Data not available

FCF Margin

N/A

—

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

Debt / Equity

4.27

Heavy debt load (4.27)

Interest Cover

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

P/E Ratio (TTM)

N/M

no trend

Negative earnings — P/E not meaningful

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial